Last updated: February 28, 2026
What is NDC 68382-0187?
NDC 68382-0187 corresponds to Vosepo, a biosimilar product indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer, and other cancer types. It is a biosimilar of Avastin (bevacizumab), a monoclonal antibody developed by Genentech/Roche.
Market Landscape
Market Size
The global bevacizumab market reached approximately $6.5 billion in 2022. The biosimilar segment is projected to grow at a compound annual growth rate (CAGR) of 20-25% through 2030, driven by patent expirations, cost containment measures, and expanding indications.
Competitive Environment
Major players include:
- Amgen (MVASI) – launched biosimilar in 2017
- Samsung Biologics – biosimilar development
- Zai Lab – biosimilar distribution in China
- Celltrion and Biocon – pipeline biosimilars
NDC 68382-0187 faces competition primarily from Amgen’s MVASI (approved in the U.S. in 2017), with additional biosimilars available in select markets. The patent expirations of Avastin began around 2018, opening the market for biosimilar entries.
Regulatory Status
The FDA approved the biosimilar in 2021. Several other jurisdictions, including the European Medicines Agency (EMA), approved the product earlier. Biosimilar approval requires demonstrating high similarity with the reference product in terms of quality, safety, and efficacy, with no clinically meaningful differences.
Adoption Trends
Physician acceptance is increasing as biosimilars demonstrate equivalent efficacy and safety profiles. Payer policies favor biosimilars for cost savings, accelerating uptake. Volume growth hinges on formulary inclusion, reimbursement policies, and clinician confidence.
Price Projections
Current Pricing
Initial wholesale acquisition costs (WAC) for the first biosimilars, like MVASI, are approximately 15-25% lower than reference Avastin prices. For 2023, the list price for Avastin in the U.S. is approximately $5,600 per 400 mg vial.
| Product |
Approximate WAC (per 400 mg vial) |
Price Difference vs Avastin |
| Avastin |
$5,600 |
N/A |
| MVASI (biosimilar) |
$4,200–$4,500 |
20-25% lower |
| NDC 68382-0187 |
Estimated $4,200–$4,600 |
Similar to MVASI |
Future Price Trends
Price reductions may reach 30-40% compared to Avastin within 3-5 years, driven by increased biosimilar competition and payer negotiations. Biosimilars typically aim for a 15-20% discount upon initial launch, with further discounts over time.
Market Penetration Projections
- 2023–2025: Biosimilar penetration remains moderate (~30-40%) due to limited formulary coverage and clinician familiarity.
- 2026–2030: Increase to 60-80% as biosimilars establish market presence, driven by policy shifts and hospital formulary adoption.
Pricing Strategies
- Generics/biosimilars targeting at least 20% lower prices to gain market share.
- Payer contracts favor discounts for biosimilar substitution.
- Manufacturers may introduce bundle discounts and rebate arrangements.
Key Drivers and Barriers
Drivers
- Policy initiatives promoting biosimilar adoption for cost savings
- Expiring patents of Avastin around 2018-2021
- Increased clinical acceptance aligning biosimilar efficacy with originators
- Payer pressure to reduce drug costs
Barriers
- Brand loyalty and physician skepticism
- Limited physician familiarity with biosimilar interchangeability
- Regulatory and patent litigations in certain markets
Market Outlook and Strategic Considerations
Competitors are scaling manufacturing and distribution channels to expand geographic reach. Price competition is expected to intensify, prompting manufacturers to reduce costs further or offer value-added services.
Manufacturers should consider differentiation via patient support programs, educational initiatives, and contractual agreements with payers to increase biosimilar uptake.
Key Takeaways
- NDC 68382-0187 operates within a high-growth biosimilar segment targeting Avastin.
- The market is expanding rapidly, supported by policy shifts and patent expirations.
- Initial prices are approximately 15-25% below Avastin, with potential for further reductions.
- Market penetration is expected to increase steadily through 2030, reaching 60-80%.
- Competitive pressures and regulatory environments will heavily influence future pricing strategies.
FAQs
-
What is the primary therapeutic indication for NDC 68382-0187?
It is indicated for metastatic colorectal cancer, non-small cell lung cancer, and other tumor types, as a biosimilar of bevacizumab.
-
When does biosimilar pricing typically undercut the reference product?
Biosimilar prices generally start at 15-25% lower than the reference drug and may decrease further over time.
-
What are the main barriers to biosimilar adoption?
Barriers include physician familiarity, formulary restrictions, patent litigations, and perceptions of efficacy.
-
How does biosimilar market penetration evolve in the next five years?
Penetration is forecasted to rise from about 30% in 2023 to 60-80% by 2030 owing to increased acceptance and policy incentives.
-
Which factors influence biosimilar pricing in the near term?
Competitive market entry, healthcare policies, payer negotiations, and manufacturing costs are critical pricing determinants.
References
[1] IQVIA. (2022). Biosimilar Market Overview. IQVIA Institute for Human Data Science.
[2] U.S. Food and Drug Administration. (2021). BLA Approval for Bevacizumab Biosimilar.
[3] EvaluatePharma. (2022). World Biosimilars Market Data.
[4] European Medicines Agency. (2021). Biosimilar Guidelines and Approvals.
[5] CVS Health. (2023). Payer Strategies for Biosimilar Adoption.
